COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,549 Articles (22,400 medRxiv, 8,149 bioRxiv)

Most recent first Previous |  Page 710: Articles 7091-7100  | Next

Variation in the ACE2 receptor has limited utility for SARS-CoV-2 host prediction
Mollentze, N., Keen, D., Munkhbayar, U., Biek, R., Streicker, D. G.
10.1101/2022.05.16.492068 — Posted: 2022-05-17
United States' political climates and the spread of SARS-2-COVID-19 during 2020
Pratto, F., Cortopassi, A., Marrouch, N.
10.1101/2022.05.16.22275162 — Posted: 2022-05-17
Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS
Batra, R., Wahlen, W., Alvarez-Mulett, S., Hoffman, K., Simmons, W., Harrington, J., Chetnik, K., Buyukozkan, M., Benedetti, E., Choi, M. E., Suhre, K., Schmidt, F., Schenck, E., Choi, A. M. K., Cho, S. J., Krumsiek, J.
10.1101/2022.05.16.22274587 — Posted: 2022-05-17
Severity of dental caries in New York City children receiving school-based prevention and the role of SARS-Cov-2: Results from the CariedAway pragmatic trial
Ruff, R. R., Barry-Godin, T., Whittemore, R., Small, T. M., Santiago-Galvin, N., Sharma, P.
10.1101/2022.05.16.22275165 — Posted: 2022-05-17
A hybrid approach to predict COVID-19 cases using neural networks and inverse problem
Paul, S., Lorin, E.
10.1101/2022.05.17.22275205 — Posted: 2022-05-17
Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial
Shah, M. R., Fatima, S., Khan, S. N., Ullah, S., Himani, G., Wan, K. H., Lin, T. P. H., Lau, J. Y., Liu, Q., Lam, D. S. C.
10.1101/2022.05.16.22275074 — Posted: 2022-05-17
Antibody response to SARS-CoV2 among COVID-19 confirmed cases, and correlates with neutralizing assay in a subgroup of patients in Delhi National Capital Region, India
Misra, P., Kant, S., Guleria, R., Rai, S., Jaiswal, A., Mandal, S., Medigeshi, G. R., Ahmad, M., Rahman, A., Sangral, M., Yadav, K., Bairwa, M., Haldar, P., Kumar, P.
10.1101/2022.05.17.22275193 — Posted: 2022-05-17
Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination.
Kenny, G., Negi, R., O'Reilly, S., Garcia Leon, A. A., Alalwan, D., Gaillard, C. M., Saini, G., Inzitari, R., Feeney, E., Cotter, A. G., de Barra, E., Sadlier, C., Crispie, F., Gautier, V., Mallon, P., All Ireland Infectious Diseases Cohort Study
10.1101/2022.05.16.22275163 — Posted: 2022-05-17
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T., Fukuhara, T., Ichihashi, G., Sanaki, T., Baba, K., Takeda, Y., Tsuge, Y., Uehara, T.
10.1101/2022.05.17.22275027 — Posted: 2022-05-17
WHAT ARE EFFECTIVE STRATEGY TO CONSTRAIN COVID-19 PANDEMIC CRISIS? LESSONS LEARNED FROM A COMPARATIVE POLICY ANALYSIS BETWEEN ITALIAN REGIONS TO COPE WITH NEXT PANDEMIC IMPACT
Coccia, M., Benati, I.
10.1101/2022.05.15.22275107 — Posted: 2022-05-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).